 The study reports the development of a dual-targeted extracellular vesicle, DTEV, that carries high loads of therapeutic RNA and effectively suppresses large pancreatic ductal adenocarcinoma, PDAC, tumors in mice. The EV surface contains a CD64 protein with a tissue targeting peptid and a humanized monoclonal antibody, which allows for specific delivery to the tumor site. Cells are transfected with plasmid DNAs encoding for the RNA and protein of interest using transwell-based asymmetric cell electroporation, resulting in abundant targeted EVs with high RNA loading. The study demonstrates that DTEVs, when used in combination with a low-dose chemotherapy drug, gemsetobene, can suppress large orthotopic PANC1 and patient-derived xenograft tumors and metastasis in mice, extending animal survival. The work presents a clinically accessible and scalable way to produce abundant EVs for delivering multiple gene cargos to large solid tumors. This article was authored by Ki-Ling Chang, Yee Fun Ma, Y. H. N. Hu, and others. We are article.tv, links in the description below.